{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:11:53Z","timestamp":1793142713349,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Steno Diabetes Center Copenhagen, Gentofte"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40265-021-01499-w","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T09:02:59Z","timestamp":1620464579000},"page":"1003-1030","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":126,"title":["A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes"],"prefix":"10.1007","volume":"81","author":[{"given":"Andreas","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip Krag","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,8]]},"reference":[{"issue":"12","key":"1499_CR1","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J. Management of hyperglycemia in type 2\u00a0diabetes, 2018. A consensus\u00a0report by the American\u00a0Diabetes\u00a0Association (ADA) and the European Association for the Study of\u00a0Diabetes\u00a0(EASD). Diabetes Care. 2018;41(12):2669\u2013701.","journal-title":"Diabetes Care"},{"issue":"1","key":"1499_CR2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/CS-2019-0472","volume":"26","author":"AJ Garber","year":"2020","unstructured":"Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142020 executive summary. Endocr Pract. 2020;26(1):107\u201339.","journal-title":"Endocr Pract."},{"issue":"8","key":"1499_CR3","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s40261-019-00826-0","volume":"39","author":"KA Lyseng-Williamson","year":"2019","unstructured":"Lyseng-Williamson KA. Glucagon-like peptide-1 receptor agonists in type-2 diabetes: their uses and differential features. Clin Drug Invest. 2019;39(8):805\u201319.","journal-title":"Clin Drug Invest"},{"issue":"2","key":"1499_CR4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/jdi.12911","volume":"10","author":"B Ahr\u00e9n","year":"2019","unstructured":"Ahr\u00e9n B. Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a rational drug development. J Diabetes Investig. 2019;10(2):196\u2013201.","journal-title":"J Diabetes Investig"},{"issue":"19","key":"1499_CR5","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"1499_CR6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"10193","key":"1499_CR7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"10157","key":"1499_CR8","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"issue":"suppl 1","key":"1499_CR9","first-page":"S90","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. 9 Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142020. Diabetes Care. 2020;43(suppl 1):S90-102.","journal-title":"Diabetes Care"},{"issue":"2","key":"1499_CR10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","volume":"63","author":"JB Buse","year":"2020","unstructured":"Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the study of Diabetes (EASD). Diabetologia. 2020;63(2):221\u20138.","journal-title":"Diabetologia"},{"issue":"5","key":"1499_CR11","doi-asserted-by":"crossref","first-page":"e205411","DOI":"10.1001\/jamanetworkopen.2020.5411","volume":"3","author":"LG Gilstrap","year":"2020","unstructured":"Gilstrap LG, Blair RA, Huskamp HA, Zelevinsky K, Normand S. Assessment of second-generation diabetes medication initiation among medicare enrollees from 2007 to 2015. JAMA Netw Open. 2020;3(5):e205411.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1499_CR12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40268-019-0273-0","volume":"19","author":"KS Boye","year":"2019","unstructured":"Boye KS, Stein D, Matza LS, Jordan J, Yu R, Norrbacka K, et al. Timing of GLP-1 receptor agonist initiation for treatment of type 2 diabetes in the UK. Drugs R D. 2019;19(2):213\u201325.","journal-title":"Drugs R D."},{"key":"1499_CR13","unstructured":"Byetta. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/byetta-epar-product-information_en.pdf. Accessed 17 Aug 2020."},{"key":"1499_CR14","unstructured":"Lyxumia. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lyxumia-epar-product-information_en.pdf. Accessed 17 Aug 2020."},{"key":"1499_CR15","unstructured":"Victoza. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/victoza-epar-product-information_en.pdf. Accessed 17 Aug 2020."},{"key":"1499_CR16","unstructured":"Ozempic. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ozempic-epar-product-information_en.pdf. Accessed 17 Aug 2020."},{"key":"1499_CR17","unstructured":"Trulicity. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trulicity-epar-product-information_en.pdf. Accessed 17 Aug 2020."},{"key":"1499_CR18","unstructured":"Bydureon. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bydureon-epar-product-information_en.pdf. Accessed 17 Aug 2020."},{"key":"1499_CR19","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2147\/PPA.S101821","volume":"10","author":"KD Stewart","year":"2016","unstructured":"Stewart KD, Johnston JA, Matza LS, Curtis SE, Havel HA, Sweetana SA, et al. Preference for pharmaceutical formulation and treatment process attributes. Patient Prefer Adherence. 2016;10:1385\u201399.","journal-title":"Patient Prefer Adherence"},{"issue":"11","key":"1499_CR20","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.4155\/tde.13.104","volume":"4","author":"BJ Bruno","year":"2013","unstructured":"Bruno BJ, Miller GD, Lim CS. Basics and recent advances in peptide and protein drug delivery. Ther Deliv. 2013;4(11):1443\u201367.","journal-title":"Ther Deliv"},{"issue":"18","key":"1499_CR21","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau J, Bloch P, Sch\u00e4ffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370\u201380.","journal-title":"J Med Chem."},{"key":"1499_CR22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"LB Knudsen","year":"2019","unstructured":"Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155.","journal-title":"Front Endocrinol"},{"issue":"5","key":"1499_CR23","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jcph.443","volume":"55","author":"C Kaptiza","year":"2015","unstructured":"Kaptiza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol\/levonorgestrel. J Clin Pharmacol. 2015;55(5):497\u2013504.","journal-title":"J Clin Pharmacol"},{"key":"1499_CR24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejps.2016.12.036","volume":"108","author":"L Jensen","year":"2017","unstructured":"Jensen L, Helleberg H, Roffel A, van Lier JJ, Bj\u00f8rnsdottir I, Pedersen PJ, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;108:101\u201310.","journal-title":"Eur J Pharm Sci"},{"issue":"467","key":"1499_CR25","doi-asserted-by":"crossref","first-page":"7047","DOI":"10.1126\/scitranslmed.aar7047","volume":"10","author":"ST Buckley","year":"2018","unstructured":"Buckley ST, B\u00e6kdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-R\u00f8nne J, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047.","journal-title":"Sci Transl Med."},{"issue":"6","key":"1499_CR26","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40262-018-0728-4","volume":"58","author":"C Granhall","year":"2019","unstructured":"Granhall C, Donsmark M, Blicher TM, Golor G, S\u00f8ndergaard FL, Thomsen M, et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet. 2019;58(6):781\u201391.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"1499_CR27","first-page":"A322","volume":"66","author":"ST Buckley","year":"2017","unstructured":"Buckley ST, Sch\u00e9ele SG, Kirk RK, Knudsen LB. Mechanism of absorption mediated by SNAC in an oral formulation of semaglutide. Diabetes. 2017;66(Suppl 1):A322.","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"1499_CR28","first-page":"A321","volume":"66","author":"SJ Maarbjerg","year":"2017","unstructured":"Maarbjerg SJ, Borregaard J, Breitschaft A, Donsmark M, S\u00f8ndergaard FL. Evaluation of the effect of food on the pharmacokinetics of oral semaglutide. Diabetes. 2017;66(Suppl 1):A321.","journal-title":"Diabetes"},{"key":"1499_CR29","unstructured":"Rybelsus. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rybelsus-epar-product-information_en.pdf. Accessed 17 Aug 2020."},{"issue":"Suppl 1","key":"1499_CR30","first-page":"S319","volume":"66","author":"A Connor","year":"2017","unstructured":"Connor A, Donsmark M, Hartoft-Nielsen M-L, S\u00f8ndergaard FL, B\u00e6kdal TA. A pharmacoscintigraphic study of the relationship between tablet erosion and pharmacokinetics of oral semaglutide. Diabetes. 2017;66(Suppl 1):S319.","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"1499_CR31","first-page":"A315","volume":"66","author":"TA B\u00e6kdal","year":"2017","unstructured":"B\u00e6kdal TA, Borregaard J, Donsmark M, Breitschaft A, S\u00f8ndergaard FL. Evaluation of the effects of water volume with dosing and post-dose fasting period on pharmacokinetics of oral semaglutide. Diabetes. 2017;66(Suppl 1):A315.","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"1499_CR32","first-page":"SAT-40","volume":"3","author":"C Hauge","year":"2019","unstructured":"Hauge C, Breitschaft A, Hartoft-Nielsen ML, Jensen S, Baekdal T. SAT-140: a drug\u2013drug interaction trial of oral semaglutide with levothyroxine and multiple co-administered tablets. J Endocr Soc. 2019;3(Suppl 1):SAT-140.","journal-title":"J Endocr Soc"},{"issue":"Suppl 1","key":"1499_CR33","first-page":"A187","volume":"22","author":"RV Overgaard","year":"2020","unstructured":"Overgaard RV, Navarria A, Hertz CL, Ingwersen SH. Similar efficacy and gastrointestinal tolerability versus exposure for oral and subcutaneous semaglutide. Diabetes Technol Ther. 2020;22(Suppl 1):A187\u20138.","journal-title":"Diabetes Technol Ther"},{"issue":"8","key":"1499_CR34","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/17425255.2018.1488965","volume":"14","author":"TA B\u00e6kdal","year":"2018","unstructured":"B\u00e6kdal TA, Breitchaft A, Navarria A, Hansen CW. A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide. Exp Opin Drug Metab Toxicol. 2018;14(8):869\u201377.","journal-title":"Exp Opin Drug Metab Toxicol"},{"issue":"Suppl 1","key":"1499_CR35","doi-asserted-by":"crossref","first-page":"1013P","DOI":"10.2337\/db19-1013-P","volume":"68","author":"JJ Meier","year":"2019","unstructured":"Meier JJ, Granhall C, Hoevelmann U, Navarria A Sr, Plum-Moerschel L, Ramesh C, et al. Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes. Diabetes. 2019;68(Suppl 1):1013P.","journal-title":"Diabetes"},{"issue":"12","key":"1499_CR36","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s40262-018-0649-2","volume":"57","author":"C Granhall","year":"2018","unstructured":"Granhall C, S\u00f8ndergaard FL, Thomsen M, Anderson TW. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. Clin Pharmacokinet. 2018;57(12):1571\u201380.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1499_CR37","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/jcph.1131","volume":"58","author":"TA B\u00e6kdal","year":"2018","unstructured":"B\u00e6kdal TA, Thomsen M, Kup\u010dov\u00e1 V, Hansen CW, Anderson TW. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J Clin Pharmacol. 2018;58(10):1314\u201323.","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 1","key":"1499_CR38","first-page":"S26","volume":"62","author":"K Dahl","year":"2019","unstructured":"Dahl K, Blundell J, Gibbons C, Brooks A, Almazedi F, Hoff S, et al. Oral semaglutide improves postprandial glucose and lipid metabolism and delays first-hour gastric emptying in subjects with type 2 diabetes. Diabetologia. 2019;62(Suppl 1):S26 [Abstract 50].","journal-title":"Diabetologia"},{"key":"1499_CR39","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/dom.13120","volume":"20","author":"JB Hjerpsted","year":"2018","unstructured":"Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves post-prandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20:610\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"1499_CR40","first-page":"S363","volume":"62","author":"J Blundell","year":"2019","unstructured":"Blundell J, Gibbons C, Hoff ST, Dahl K, S\u00f8ndergaard FL, B\u00e6kdal TA. Oral semaglutide reduces appetite and energy intake and improves control of eating in subjects with type 2 diabetes. Diabetologia. 2019;62(Suppl 1):S363 [Abstract 753].","journal-title":"Diabetologia"},{"key":"1499_CR41","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","volume":"19","author":"J Blundell","year":"2017","unstructured":"Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19:1242\u201351.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"1499_CR42","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40262-019-00756-2","volume":"58","author":"TA B\u00e6kdal","year":"2019","unstructured":"B\u00e6kdal TA, Borregaard J, Hansen CW, Thomsen M, Anderson TW. Effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin in healthy subjects. Clin Pharmacokinet. 2019;58(9):1193\u2013203.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"1499_CR43","first-page":"S346","volume":"61","author":"TA B\u00e6kdal","year":"2018","unstructured":"B\u00e6kdal TA, Albayaty M, Manigandan E, Anderson TW, Skibsted S. A trial to investigate the effect of oral semaglutide on the pharmacokinetics of furosemide and rosuvastatin in healthy subjects. Diabetologia. 2018;61(Suppl 1):S346\u20137.","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"1499_CR44","first-page":"S346","volume":"61","author":"AB Jordy","year":"2018","unstructured":"Jordy AB, Breitschaft A, Christiansen E, Granhall C, Hansen CW, Houshmand-\u00d8regaard A, et al. Oral semaglutide does not affect the bioavailability of the combined oral contraceptive, ethinylestradiol\/levonorgestrel. Diabetologia. 2018;61(Suppl 1):S346.","journal-title":"Diabetologia"},{"issue":"15","key":"1499_CR45","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460\u201370.","journal-title":"JAMA"},{"issue":"9","key":"1499_CR46","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","volume":"42","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724\u201332.","journal-title":"Diabetes Care"},{"issue":"12","key":"1499_CR47","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","volume":"42","author":"HW Rodbard","year":"2019","unstructured":"Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg S\u00d8, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272\u201381.","journal-title":"Diabetes Care"},{"issue":"15","key":"1499_CR48","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466\u201380.","journal-title":"JAMA"},{"issue":"10192","key":"1499_CR49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","volume":"394","author":"RE Pratley","year":"2019","unstructured":"Pratley RE, Amod A, Tetens Hoff S, Kadowaki T, Lingvay I, Nauck M, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39\u201350.","journal-title":"Lancet"},{"issue":"7","key":"1499_CR50","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515\u201327.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1499_CR51","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"7","key":"1499_CR52","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","volume":"7","author":"TR Pieber","year":"2019","unstructured":"Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528\u201339.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"1499_CR53","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","volume":"42","author":"B Zinman","year":"2019","unstructured":"Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Tetens Hoff S, et al. Efficacy, safety and tolerability of oral semaglutide versus placebo added to insulin \u00b1 metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42(12):2262\u201371.","journal-title":"Diabetes Care"},{"issue":"5","key":"1499_CR54","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","volume":"8","author":"Y Yamada","year":"2020","unstructured":"Yamada Y, Katagiri H, Hamamoto Y, Deenadayalan S, Navarria A, Nishijima K, et al. Dose-response, efficacy and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2\/3a, randomised, multicentre trial. Lancet Diabetes Endocrinol. 2020;8(5):377\u201391.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1499_CR55","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","volume":"8","author":"D Yabe","year":"2020","unstructured":"Yabe D, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, Gislum M, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2020;8(5):392\u2013406.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 1","key":"1499_CR56","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc20-S010","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes\u20142020. Diabetes Care. 2020;43(Suppl 1):S111\u201334.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"1499_CR57","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.2337\/dc20-S011","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes\u20142020. Diabetes Care. 2020;43(Suppl 1):S135\u201351.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"1499_CR58","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.2337\/dc20-S006","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes\u20142020. Diabetes Care. 2020;43(Suppl 1):S66-76.","journal-title":"Diabetes Care"},{"key":"1499_CR59","doi-asserted-by":"publisher","DOI":"10.2337\/db20-964-P","author":"KM Dungan","year":"2020","unstructured":"Dungan KM, Hertz CL, Mellbin L, Abildlund Nielsen M, S\u00f8rrig R, Woo VC, et al. 964-P: glycemic and body weight responses to oral semaglutide in the PIONEER trial program. Diabetes. 2020;69(Suppl 1). https:\/\/doi.org\/10.2337\/db20-964-P.","journal-title":"Diabetes"},{"issue":"9","key":"1499_CR60","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3390\/ijerph15050947","volume":"15","author":"Y Saisho","year":"2018","unstructured":"Saisho Y. Use of Diabetes Treatment Satisfaction Questionnaire in diabetes care: importance of patient-reported outcomes. Int J Environ Res Public Health. 2018;15(9):947.","journal-title":"Int J Environ Res Public Health"},{"issue":"Suppl 3","key":"1499_CR61","doi-asserted-by":"crossref","first-page":"S593","DOI":"10.1016\/j.jval.2019.09.999","volume":"22","author":"BB Hansen","year":"2019","unstructured":"Hansen BB, Hertz CL, Tarp-Johansen MJ. Patient treatment and study staff perceptions of oral semaglutide for the treatment of type 2 diabetes. Value Health. 2019;22(Suppl 3):S593\u20134.","journal-title":"Value Health"},{"issue":"12","key":"1499_CR62","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/ejcn.2015.57","volume":"69","author":"M Dalton","year":"2015","unstructured":"Dalton M, Finlayson G, Hill A, Blundell J. Preliminary validation and principal components analysis of the control of eating questionnaire (CoEQ) for the experience of food craving. Eur J Clin Nutr. 2015;69(12):1313\u20137.","journal-title":"Eur J Clin Nutr"},{"issue":"Suppl 1","key":"1499_CR63","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dom.13162","volume":"20","author":"VR Aroda","year":"2018","unstructured":"Aroda VR. A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomized controlled trials. Diabetes Obes Metab. 2018;20(Suppl 1):22\u201333.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1499_CR64","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/dom.13553","volume":"21","author":"SC Bain","year":"2019","unstructured":"Bain SC, Mosenzon O, Archavaleta R, Bogda\u0144ski P, Comlekci A, Consoli A, et al. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes Obes Metab. 2019;21(3):499\u2013508.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1499_CR65","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/dom.13955","volume":"22","author":"M Husain","year":"2020","unstructured":"Husain M, Bain SC, Jeppesen OK, Lingvay I, S\u00f8rrig R, Treppendahl MB, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020;22(3):442\u201351.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"1499_CR66","first-page":"A-185","volume":"22","author":"M Haluz\u00edk","year":"2020","unstructured":"Haluz\u00edk M, Bauer R, Eriksson J, Hoff ST, Kallenbach K, Pratley RE, et al. Efficacy of oral semaglutide according to diabetes duration: an exploratory subgroup analysis of the PIONEER trial programme. Diab Technol Ther. 2020;22(Suppl 1):A-185.","journal-title":"Diab Technol Ther"},{"key":"1499_CR67","doi-asserted-by":"publisher","DOI":"10.2337\/db20-932-P","author":"VR Aroda","year":"2020","unstructured":"Aroda VR, Bauer R, Hertz CL, Montanya E, S\u00f8rrig R, Warren ML, et al. 932-P: efficacy and safety of oral semaglutide by baseline age in the PIONEER clinical trial program. Diabetes. 2020;69(Suppl 1). https:\/\/doi.org\/10.2337\/db20-932-P.","journal-title":"Diabetes"},{"key":"1499_CR68","doi-asserted-by":"publisher","DOI":"10.2337\/db20-930-P","author":"C Desouza","year":"2020","unstructured":"Desouza C, Amod A, Kallenbach K, Lin PJ, Abildlund Nielsen M, S\u00f8rrig R, et al. 930-P: efficacy of oral semaglutide according to race: an exploratory sub-group analysis of the PIONEER trial program. Diabetes. 2020;69(Suppl 1). https:\/\/doi.org\/10.2337\/db20-930-P.","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"1499_CR69","first-page":"S27","volume":"62","author":"J Meier","year":"2019","unstructured":"Meier J, Bauer R, Blicher TM. Efficacy of oral semaglutide according to baseline HbA1c: an exploratory sub-group analysis of the PIONEER trial programme. Diabetologia. 2019;62(Suppl 1):S27 [Abstract 51].","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"1499_CR70","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2337\/db19-111-LB","volume":"68","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Allison DC, Birkenfeld AL, Blicher TM, Deenadayalan S, Kousholt A, et al. Oral semaglutide vs sitagliptin: efficacy by baseline HbA1c and background OAD in PIONEER 3. Diabetes. 2019;68(Suppl 1):111-LB.","journal-title":"Diabetes"},{"key":"1499_CR71","doi-asserted-by":"publisher","DOI":"10.2337\/db20-957-P","author":"JB Buse","year":"2020","unstructured":"Buse JB, Crowley M, Eriksson JW, Gislum M, Hertz CL, Kaiser M, et al. 957-P: efficacy of oral semaglutide according to background medication: an exploratory analysis of the PIONEER trial program. Diabetes. 2020;69(Suppl 1). https:\/\/doi.org\/10.2337\/db20-957-P.","journal-title":"Diabetes"},{"key":"1499_CR72","doi-asserted-by":"publisher","DOI":"10.2337\/db20-927-P","author":"RE Pratley","year":"2020","unstructured":"Pratley RE, Bauer R, Inzucchi SE, Khunti K, Kreiner EB, Laursen PN, et al. 927P: effect of oral semaglutide with or without background SGLT2i in patients with T2D: subgroup analysis of PIONEER 4. Diabetes. 2020;69(Suppl 1). https:\/\/doi.org\/10.2337\/db20-927-P.","journal-title":"Diabetes"},{"key":"1499_CR73","doi-asserted-by":"publisher","DOI":"10.2337\/db20-956-P","author":"O Mosenzon","year":"2020","unstructured":"Mosenzon O, Aroda VR, Christiansen E, Harris SB, Boje Pedersen K, Tarp-Johansen MJ, et al. 956-p: efficacy and safety of oral semaglutide when added to basel, premix, or basel-bolus insulin. Diabetes. 2020;69(Suppl 1). https:\/\/doi.org\/10.2337\/db20-956-P.","journal-title":"Diabetes"},{"issue":"6","key":"1499_CR74","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/13696998.2020.1722678","volume":"23","author":"BB Hansen","year":"2020","unstructured":"Hansen BB, Nuhoho S, Ali SN, Dang-Tan T, Valentine WJ, Malkin SJP, et al. Oral semaglutide versus injectable glucagon like peptide-1 receptor agonists: a cost of control analysis. J Med Econ. 2020;23(6):650\u20138.","journal-title":"J Med Econ"},{"issue":"12","key":"1499_CR75","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1007\/s12325-019-01125-y","volume":"36","author":"B Hunt","year":"2019","unstructured":"Hunt B, Hansen BB, Ericsson \u00c5, Kallenbach K, Ali SN, Dang-Tan T, et al. Evaluation of the cost per patient achieving treatment targets with oral semaglutide: a short-term cost-effectiveness analysis in the United States. Adv Ther. 2019;36(12):3483\u201393.","journal-title":"Adv Ther"},{"issue":"1","key":"1499_CR76","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s13300-019-00736-6","volume":"11","author":"SC Bain","year":"2020","unstructured":"Bain SC, Hansen BB, Malkin SJP, Nuhoho S, Valentine WJ, Chubb B, et al. Oral semaglutide versus empagliflozin, sitagliptin and liraglutide in the UK: long-term cost-effectiveness analyses based on the PIONEER clinical trial programme. Diabetes Ther. 2020;11(1):259\u201377.","journal-title":"Diabetes Ther"},{"key":"1499_CR77","doi-asserted-by":"publisher","DOI":"10.2337\/db20-1163-P","author":"AR Liu","year":"2020","unstructured":"Liu AR, Bech PG, Fridhammer A, Nilsson A, Willis M, Nuhoho S. 1163P: cost-effectiveness of oral semalgutide 14 mg versus empagliflozin 25 mg. Diabetes. 2020;69(Suppl 1). https:\/\/doi.org\/10.2337\/db20-1163-P.","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"1499_CR78","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.jval.2020.04.232","volume":"23","author":"A Alsumali","year":"2020","unstructured":"Alsumali A, Lautsch D, Kowal S, Li Q, Campbell C, Rajpathak S, et al. The budget impact of sitagliptin versus oral semaglutide from a US payer perspective. Value Health. 2020;23(Suppl 1):S116.","journal-title":"Value Health"},{"issue":"2","key":"1499_CR79","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2337\/dc09-1348","volume":"33","author":"M Peyrot","year":"2010","unstructured":"Peyrot M, Rubi RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240\u20135.","journal-title":"Diabetes Care"},{"issue":"3","key":"1499_CR80","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12325-016-0470-y","volume":"34","author":"H Nguygen","year":"2017","unstructured":"Nguygen H, Dufour R, Caldwell-Tarr A. Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy adherence for patients with type 2 diabetes in a medicare population. Adv Ther. 2017;34(3):658\u201373.","journal-title":"Adv Ther"},{"issue":"1","key":"1499_CR81","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/13696998.2019.1645018","volume":"23","author":"SC Bain","year":"2020","unstructured":"Bain SC, Hansen BB, Hunt B, Chubb B, Valentine WL. Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. J Med Econ. 2020;23(1):98\u2013105.","journal-title":"J Med Econ"},{"issue":"6","key":"1499_CR82","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s13300-019-00706-y","volume":"10","author":"S Nuhoho","year":"2019","unstructured":"Nuhoho S, Gupta J, Hansen BB, Fletcher-Louis M, Dang-Tan T, Paine A. Orally administered semaglutide versus GLP-1 RAs in patients with type 2 diabetes previously receiving 1\u20132 oral antidiabetics: systematic review and network meta-analysis. Diabetes Ther. 2019;10(6):2183\u201399.","journal-title":"Diabetes Ther"},{"issue":"4","key":"1499_CR83","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/dom.12596","volume":"18","author":"S Madsbad","year":"2016","unstructured":"Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18(4):317\u201332.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"1499_CR84","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/dom.12534","volume":"17","author":"J Miyagawa","year":"2015","unstructured":"Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, Imaoka T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab. 2015;17(10):974\u201383.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1499_CR85","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/dom.12602","volume":"18","author":"M Odawara","year":"2016","unstructured":"Odawara M, Miyagawa J, Iwamoto N, Takita Y, Imaoka T, Takamura T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study. Diabetes Obes Metab. 2016;18(3):249\u201357.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1499_CR86","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/dom.13082","volume":"20","author":"Y Seino","year":"2018","unstructured":"Seino Y, Terauchi Y, Osonoi T, Yabe D, Abe N, Nishida T, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):378\u201388.","journal-title":"Diabetes Obes Metab"},{"key":"1499_CR87","doi-asserted-by":"publisher","unstructured":"Alfayez O, Alkhezi O, Almutairi AR. 455-P: network meta-analysis of seven glucagon-like peptide-1 receptor agonists: a focus on cardiovascular outcomes trials data. Diabetes. 2020;69(Suppl 1). https:\/\/doi.org\/10.2337\/db20-445-P.","DOI":"10.2337\/db20-445-P"},{"key":"1499_CR88","unstructured":"Clinicaltrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03914326. Accessed 2 Jun 2020."},{"key":"1499_CR89","doi-asserted-by":"publisher","DOI":"10.2337\/db20-2216-PUB","author":"G Savarese","year":"2020","unstructured":"Savarese G, Sharma A, Pang C, Wood R, George JT, Soleymanlou N. Patient preferences for newer oral therapies in type 2 diabetes. Diabetes. 2020;69(Suppl 1). https:\/\/doi.org\/10.2337\/db20-2216-PUB.","journal-title":"Diabetes"},{"key":"1499_CR90","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14244","author":"K Boye","year":"2020","unstructured":"Boye K, Ross M, Mody R, Konig M, Gelhorn H. Patients\u2019 preferences for once-daily oral versus once-weekly injectable diabetes medications: the REVISE study. Diabetes Obes Metab. 2021;23(2):508\u2013519.","journal-title":"Diabetes Obes Metab"},{"key":"1499_CR91","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01561-1","author":"A Igarashi","year":"2020","unstructured":"Igarashi A, Hansen BB, Langer J, Tavella F, Collings H, Davies N, et al. Preference for oral and injectable GLP-1RA therapy profiles in Japanese patients with type 2 diabetes: a discrete choice experiment. Adv Ther. 2021;38(1):721\u2013738.","journal-title":"Adv Ther"},{"issue":"5","key":"1499_CR92","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2337\/dc12-2480","volume":"36","author":"ER Seaquist","year":"2013","unstructured":"Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384\u201395.","journal-title":"Diabetes Care"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01499-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01499-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01499-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T11:46:09Z","timestamp":1624275969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01499-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,8]]},"references-count":92,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1499"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01499-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,8]]},"assertion":[{"value":"6 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Incorrect xml tagging","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article was supported by Novo Nordisk; the company was provided with the opportunity to perform a medical accuracy review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Andreas Andersen declares no conflicts of interest. Filip Krag Knop has served on scientific advisory panels and\/or been part of speakers\u2019 bureaus for, served as a consultant to, and\/or received research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, MedImmune, MSD\/Merck, Mundipharma, Norgine, Novo Nordisk, Sanofi, and Zealand Pharma. Tina Vilsb\u00f8ll has served on scientific advisory panels, been part of speakers\u2019 bureaus for, served as a consultant to, and\/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gilead, Mundipharma, MSD\/Merck, Novo Nordisk, Sanofi, and Sun Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The authors directed the content and reviewed and critically revised all drafts.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}